|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
MARKET FACILITATION INDEX
Trading: SELL @ $46.9
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Ra Pharmaceuticals Inc (NASDAQ:RARX) Currently is a confirmed Fake Day.
The Market Facilitation Index is designed for evaluation the willingness of the market to move the price. The indicators absolute values alone cannot provide any trading signals unlike its dynamics in relation to the dynamics of the volume.
Calculation: Bill Williams Market Facilitation Index:
1) Green bar - both MFI and volume are up. Increasing trading activity means market movement acceleration;
2) Blue bar - MFI indicator is up volume is down. The movement is continuing although the volume has dropped. The trend will soon be reversing;
3) Pink bar - MFI indicator is down volume is up. The slowing down movement while volume is raising may indicate a possible break through often a U-turn;
4) Brown bar - both MFI and volume are down. The market is no longer interested in the current direction and is looking for signs of a future development;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|CNCE Concert Pharmaceutic||13.09||33||924,583||0||NEUTRAL|
|ARAY Accuray Incorporated||3.95||7.9||2,162,586||0||NEUTRAL|
|GBLI Global Indemnity Plc||32.56||6||9,228||0||NEUTRAL|
|XENT Intersect Ent||25.17||4.7||1,131,415||0||NEUTRAL|
|TRUP Trupanion Inc||33.32||4.2||261,897||0||NEUTRAL|
|TSLA Tesla Inc||569.55||4.1||31,140,138||0||NEUTRAL|
|CCRN Cross Country Healthcare||10.85||3.9||684,096||0||NEUTRAL|